-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*For medical professionals only, read epilepsy patients will usher in a new gospel! With the end of the publicity period, on March 30, 2022, the Center for Drug Evaluation of the State Drug Administration officially recognized Ushibi's new drug alprazolam inhalation powder (Staccato) as "breakthrough therapy", and the proposed indications For "rapid termination of prolonged seizures of stereotyped epilepsy in patients 12 years of age and older"
.
Alprazolam inhalation powder is currently in phase 3 clinical stage worldwide, and the product has been certified as "breakthrough therapy" in China, which fully proves that the drug regulatory agency has recognized the innovative solution of alprazolam inhalation powder to clinical needs.
Accelerating the launch of the product in China will benefit Chinese epilepsy patients earlier
.
As a result, alprazolam inhalation powder is expected to become the first innovative therapy in China that can rapidly terminate active seizures with on-demand, one-time treatment
.
It is very important to quickly terminate the process of epileptic seizures, and the gap in this field needs to be filled urgently.
Epilepsy is a common paroxysmal neurological disease and is listed by the World Health Organization as one of the five major intractable diseases of the nervous system [1]
.
In China, more than 9 million people suffered from epilepsy in 2013, with 400,000-600,000 new cases every year [1]
.
Epilepsy has a great impact on individual medical expenditure, and brings a heavy economic burden to patients and their families as well as Chinese society
.
Judging from the current clinical treatment methods, when the seizures are not well controlled, in addition to maintaining antiepileptic drug treatment, some patients also need acute treatment to avoid seizure exacerbation/epilepsy emergencies
.
Wang Qun, director of the Epilepsy Department of the Neurology Center of Beijing Tiantan Hospital Affiliated to Capital Medical University, said: "Time is the life of patients with grand mal epilepsy and status epilepticus, and emergency treatment to quickly terminate the process of epilepsy and prevent epilepsy recurrence is crucial
.
Globally, there are already approved home or out-of-hospital treatments for rapidly terminating epileptic seizures and preventing the progression to status epilepticus; however, in China, there is no such rescue measure for out-of-hospital first aid, and the gap in this field needs to be filled urgently.
.
"Alprazolam "breakthrough therapy" quickly terminates the process of epileptic seizures and escorts patients.
Alprazolam is a benzodiazepine derivative, and benzodiazepines are the first choice for the treatment of epilepsy emergencies [ 2]
.
Alprazolam
inhalation powder is packed in a single-dose inhaler for single use, and it is administered by oral inhalation.
It is an improved new drug
.
This product avoids the inconvenience of intravenous administration in out-of-hospital first aid.
At the same time, the specific route of administration ensures that its onset time is the same as that of intravenous administration
.
Alprazolam inhalation powder is expected to be more effective than internationally approved in the emergency treatment of epilepsy (China has not yet The existing treatment plan that has been approved) has more advantages[2]
.
Zhou Dong, director of the Department of Neurology, West China Hospital of Sichuan University, head of the epilepsy and electroencephalography group of the Neurology Branch of the Chinese Medical Association, and vice president of the China Antiepileptic Association, said: " Alprazolam inhalation powder is being developed as a novel treatment for out-of-hospital treatment of epilepsy currently worldwide - Rapid Epileptic Seizure Termination (REST) therapy
.
This therapy has the potential to quickly terminate epileptic seizures in the first place by using non-invasive drug treatment for epilepsy patients who can breathe normally, and can greatly meet the unmet medical needs of patients with a long history of epilepsy.
And to provide greater social acceptance for people with epilepsy and their families
.
We expect this innovative inhalation therapy to be launched as soon as possible, escorting the majority of epilepsy patients
.
” As a global biopharmaceutical company, UCB has continued to invest and innovate in the field of anti-epileptics, continuously expand its rich product lines in the field of epilepsy, and provide unique solutions for different patient groups
.
In 2022, Levetiracetam (Kaipu) Lan) has been on the market in China for 15 years, and has benefited more than 500,000 Chinese patients as an anti-epileptic weapon trusted by many doctors; the alprazolam inhalation powder in the clinical development process has made significant progress; in March, UCB completed the acquisition of Zogenix The company's acquisition, the flagship product fenfluramine (Fintepla) CIV oral solution has been approved in the United States and Europe for seizures associated with Dravet syndrome, and was approved in the United States on March 28 for the combination with Lennox-Gastaut Treatment of symptom-related seizures
.
Expert Profile Professor Zhou Dong Director, Professor and Doctoral Supervisor of Department of Neurology, West China Hospital, Sichuan University Currently Vice President of China Anti-epilepsy Association, Vice President of Neurology Branch of Chinese Medical Association, EEG and Epilepsy Group of Neurology Branch of Chinese Medical Association Group leader, member of the International League Against Epilepsy (ILAE) Publishing Council, member of the New Crown Working Group, member of the Functional/Dissociative Seizure Working Group, Executive Deputy Editor-in-Chief of the official magazine Epilepsia Open, Editor-in-Chief of "Journal of Epilepsy", Epilepsy Research, Seizure, The european The editorial board of journal of neurology has presided over a number of natural science foundations, and has published more than 300 papers, including more than 200 SCI papers.
Professor Wang Qun, director of the Epilepsy Department of the Neurology Center of Beijing Tiantan Hospital affiliated to Capital Medical University, chief physician, professor, Ph.
D.
Student tutor, deputy head of the EEG and Epilepsy Group of the Neurology Branch of the Chinese Medical Association, member of the Epilepsy Special Committee of the Neurology Branch of the Chinese Medical Doctor Association, and member of the Standing Committee of the Neuromodulation Special Committee.
Neuromodulation Special Committee, Vice Chairman of Epilepsy Community Management Working Committee Member of the Standing Committee of EEG and Neuroelectrophysiology Branch of China Anti-epilepsy Association and Deputy Head of the Critical Brain Function Monitoring Group Chinese Journal of Neurology, Journal of Clinical Neurology, China Modern Neurology Journal of Science, Acta Neurologica Scanidnavica, Acta Epileptologica Editorial Board Reference Source: [1] Expert Collaborative Group on Consensus on Long-term Management of Adult Epilepsy Patients.
Expert Consensus on Long-term Management of Adult Epilepsy Patients.
Chinese Journal of Neurology.
2013, 46(7): 496-499.
[2]Asnis-Alibozek A, Detyniecki K.
The unmet need for rapid epileptic seizure termination (REST).
Epilepsy Behav Rep.
2020;15:100409.
*This article is for the purpose of providing science to healthcare professionals only Information, does not represent the platform's point of view
.
Alprazolam inhalation powder is currently in phase 3 clinical stage worldwide, and the product has been certified as "breakthrough therapy" in China, which fully proves that the drug regulatory agency has recognized the innovative solution of alprazolam inhalation powder to clinical needs.
Accelerating the launch of the product in China will benefit Chinese epilepsy patients earlier
.
As a result, alprazolam inhalation powder is expected to become the first innovative therapy in China that can rapidly terminate active seizures with on-demand, one-time treatment
.
It is very important to quickly terminate the process of epileptic seizures, and the gap in this field needs to be filled urgently.
Epilepsy is a common paroxysmal neurological disease and is listed by the World Health Organization as one of the five major intractable diseases of the nervous system [1]
.
In China, more than 9 million people suffered from epilepsy in 2013, with 400,000-600,000 new cases every year [1]
.
Epilepsy has a great impact on individual medical expenditure, and brings a heavy economic burden to patients and their families as well as Chinese society
.
Judging from the current clinical treatment methods, when the seizures are not well controlled, in addition to maintaining antiepileptic drug treatment, some patients also need acute treatment to avoid seizure exacerbation/epilepsy emergencies
.
Wang Qun, director of the Epilepsy Department of the Neurology Center of Beijing Tiantan Hospital Affiliated to Capital Medical University, said: "Time is the life of patients with grand mal epilepsy and status epilepticus, and emergency treatment to quickly terminate the process of epilepsy and prevent epilepsy recurrence is crucial
.
Globally, there are already approved home or out-of-hospital treatments for rapidly terminating epileptic seizures and preventing the progression to status epilepticus; however, in China, there is no such rescue measure for out-of-hospital first aid, and the gap in this field needs to be filled urgently.
.
"Alprazolam "breakthrough therapy" quickly terminates the process of epileptic seizures and escorts patients.
Alprazolam is a benzodiazepine derivative, and benzodiazepines are the first choice for the treatment of epilepsy emergencies [ 2]
.
Alprazolam
inhalation powder is packed in a single-dose inhaler for single use, and it is administered by oral inhalation.
It is an improved new drug
.
This product avoids the inconvenience of intravenous administration in out-of-hospital first aid.
At the same time, the specific route of administration ensures that its onset time is the same as that of intravenous administration
.
Alprazolam inhalation powder is expected to be more effective than internationally approved in the emergency treatment of epilepsy (China has not yet The existing treatment plan that has been approved) has more advantages[2]
.
Zhou Dong, director of the Department of Neurology, West China Hospital of Sichuan University, head of the epilepsy and electroencephalography group of the Neurology Branch of the Chinese Medical Association, and vice president of the China Antiepileptic Association, said: " Alprazolam inhalation powder is being developed as a novel treatment for out-of-hospital treatment of epilepsy currently worldwide - Rapid Epileptic Seizure Termination (REST) therapy
.
This therapy has the potential to quickly terminate epileptic seizures in the first place by using non-invasive drug treatment for epilepsy patients who can breathe normally, and can greatly meet the unmet medical needs of patients with a long history of epilepsy.
And to provide greater social acceptance for people with epilepsy and their families
.
We expect this innovative inhalation therapy to be launched as soon as possible, escorting the majority of epilepsy patients
.
” As a global biopharmaceutical company, UCB has continued to invest and innovate in the field of anti-epileptics, continuously expand its rich product lines in the field of epilepsy, and provide unique solutions for different patient groups
.
In 2022, Levetiracetam (Kaipu) Lan) has been on the market in China for 15 years, and has benefited more than 500,000 Chinese patients as an anti-epileptic weapon trusted by many doctors; the alprazolam inhalation powder in the clinical development process has made significant progress; in March, UCB completed the acquisition of Zogenix The company's acquisition, the flagship product fenfluramine (Fintepla) CIV oral solution has been approved in the United States and Europe for seizures associated with Dravet syndrome, and was approved in the United States on March 28 for the combination with Lennox-Gastaut Treatment of symptom-related seizures
.
Expert Profile Professor Zhou Dong Director, Professor and Doctoral Supervisor of Department of Neurology, West China Hospital, Sichuan University Currently Vice President of China Anti-epilepsy Association, Vice President of Neurology Branch of Chinese Medical Association, EEG and Epilepsy Group of Neurology Branch of Chinese Medical Association Group leader, member of the International League Against Epilepsy (ILAE) Publishing Council, member of the New Crown Working Group, member of the Functional/Dissociative Seizure Working Group, Executive Deputy Editor-in-Chief of the official magazine Epilepsia Open, Editor-in-Chief of "Journal of Epilepsy", Epilepsy Research, Seizure, The european The editorial board of journal of neurology has presided over a number of natural science foundations, and has published more than 300 papers, including more than 200 SCI papers.
Professor Wang Qun, director of the Epilepsy Department of the Neurology Center of Beijing Tiantan Hospital affiliated to Capital Medical University, chief physician, professor, Ph.
D.
Student tutor, deputy head of the EEG and Epilepsy Group of the Neurology Branch of the Chinese Medical Association, member of the Epilepsy Special Committee of the Neurology Branch of the Chinese Medical Doctor Association, and member of the Standing Committee of the Neuromodulation Special Committee.
Neuromodulation Special Committee, Vice Chairman of Epilepsy Community Management Working Committee Member of the Standing Committee of EEG and Neuroelectrophysiology Branch of China Anti-epilepsy Association and Deputy Head of the Critical Brain Function Monitoring Group Chinese Journal of Neurology, Journal of Clinical Neurology, China Modern Neurology Journal of Science, Acta Neurologica Scanidnavica, Acta Epileptologica Editorial Board Reference Source: [1] Expert Collaborative Group on Consensus on Long-term Management of Adult Epilepsy Patients.
Expert Consensus on Long-term Management of Adult Epilepsy Patients.
Chinese Journal of Neurology.
2013, 46(7): 496-499.
[2]Asnis-Alibozek A, Detyniecki K.
The unmet need for rapid epileptic seizure termination (REST).
Epilepsy Behav Rep.
2020;15:100409.
*This article is for the purpose of providing science to healthcare professionals only Information, does not represent the platform's point of view
